Table 4.
Prescription of medications that affect urinary stone recurrence during the first year after incident stone diagnosis, among patients who completed at least one 24-h urine test, by subspecialty clinic visits within 6 mo of 24-h urine test
| Clinic Visit Type | Total Patients with 24-h Urine Tests (n=17,303) | Thiazide Prescriptions | Alkali Prescriptions | Allopurinol Prescriptionsa | |||
|---|---|---|---|---|---|---|---|
| 24-h Urine Calcium >200 mg/d (n=5292) | 24-h Urine Citrate ≤400 mg/d (n=5433) | 24-h Urine Uric Acid >800 mg/d (n=601) | |||||
| Participants with Clinic Visit within 6 mo of 24-h Urine Test (N, %) | Participants Receiving Medication during First Year after Diagnosis (N, %) | Difference from Baseline in Proportion of Participants Receiving Medication (%) | Participants Receiving Medication during First Year after Diagnosis (N, %) | Difference from Baseline in Proportion of Participants Receiving Medication (%) | Participants Receiving Medication during First Year after Diagnosis (N, %) | Difference from Baseline in Proportion of Participants Receiving Medication (%) | |
| Urology | 9927 (57%) | 834 (26%) | 11 | 1044 (34%) | 28 | 133 (7%) | 4 |
| Nephrology | 1887 (11%) | 171 (37%) | 17 | 366 (48%) | 35 | 54 (15%) | 5b |
| Both | 1870 (11%) | 214 (42%) | 24 | 435 (54%) | 40 | 53 (12%) | 6 |
| Neither | 3619 (21%) | 243 (21%) | 4 | 154 (19%) | 13 | 40 (8%) | 3 |
All P values were significant at <0.001 except where marked.
a
Excluding patients with gout.
b
P value 0.16.